{"prompt": "['Assuming a rate of 70% of patients preferring pertuzumab and trastuzumab FDC SC and aiming at a', 'distance from the estimated proportion to the CI limits of approximately 8%, a total of 126 patients', 'are needed for the evaluation of preference. Hence, the observed rate of 70% of patients preferring', 'pertuzumab and trastuzumab FDC SC could be estimated to be within 61.9% and 78.4% with a', 'probability of 95%.', 'To allow for 10% of the patients not providing an evaluable preference assessment, approximately', '140 patients are targeted to be randomized into the study.', 'Optional-Interim Analysis', 'An interim safety analysis may be conducted. The decision to perform an interim safety analysis will', 'be based on ongoing review of safety data by the Medical Monitor If conducted, the results of this', \"interim analysis will be evaluated by a Sponsor's Internal Data Monitoring Committee An interim\", 'analysis will be conducted to support a planned regulatory filing for FDC, which will consist of a subset of the', \"analyses planned for the primary analysis. The results of this interim analysis will be evaluated by a Sponsor's\", 'Internal Monitoring Committee. Further details will be specified in the Statistical Analysis Plan.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '25 / Protocol MO40628, Version 12']['LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Abbreviation', 'Definition', 'ACE', 'angiotensin-converting enzyme', 'ACS/ASCO', 'American Cancer Society / American Society of Clinical Oncology Breast', 'Cancer', 'ADA', 'anti-drug antibody', 'ADCC', 'antibody dependent cell-mediated cytotoxicity', 'AE', 'adverse event', 'ALT', 'alanine aminotransferase', 'ANC', 'absolute neutrophil count', 'ARDS', 'acute respiratory distress syndrome', 'ARR', 'administration-related reactions', 'AST', 'aspartate aminotransferase', 'AUC', 'area under the curve', 'AV', 'atrioventricular', 'CHF', 'congestive heart failure', 'CI', 'confidence interval', 'CRO', 'contract research organization', 'Ctrough', 'serum trough concentration', 'DDFS', 'distant disease-free survival', 'EBC', 'early breast cancer', 'EC', 'Ethics Committee', 'ECD', 'extracellular domain', 'ECG', 'electrocardiogram', 'ECHO', 'echocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'electronic Case Report Form', 'EDC', 'electronic data capture', 'EFS', 'event-free survival', 'EGFR', 'epidermal growth factor receptor', 'EORTC QLQ-C30', 'European Organization for Research and Treatment of Cancer Quality of', 'Life Questionnaire C30', 'ER', 'oestrogen receptor', 'EU', 'European Union', 'FDC SC', 'Fixed-dosed combination formulation for subcutaneous administration', 'HCG', 'human chorionic gonadotropin', 'HCP', 'healthcare professional', 'HCPQ', 'Healthcare Professional Questionnaire', 'HER2', 'human epidermal growth factor receptor 2', 'HER2+', 'HER2-positive', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '26 / Protocol MO40628, Version 12']['HER', 'human epidermal growth factor receptor', 'Herceptin IV', 'Herceptin for IV administration', 'Herceptin SC', 'Herceptin for SC administration', 'HIPPA', 'Health Insurance Portability and Accountability Act', 'HIV', 'human immunodeficiency virus', 'HRQoL', 'health-related quality of life', 'ICH', 'International Council for Harmonisation', 'IDFS', 'invasive disease-free survival', 'Ig', 'immunoglobulin', 'IHC', 'immunohistochemistry', 'IV', 'intravenous(ly)', 'IMP', 'investigational medicinal product', 'IND', 'Investigational New Drug (Application)', 'IRB', 'Institutional Review Board', 'ISH', 'in situ hybridization', 'ISR', 'injection site reaction', 'ITT', 'intent-to-treat', 'IUD', 'intrauterine device', 'IWRS', 'interactive web-based response system', 'LDH', 'lactate dehydrogenase', 'LPLV', 'last patient, last visit', 'LVEF', 'left ventricular ejection fraction', 'LVSD', 'left ventricular systolic dysfunction', 'MBC', 'metastatic breast cancer', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mITT', 'modified intent-to-treat', 'MRI', 'magnetic resonance imaging', 'MUGA', 'multiple-gated acquisition scan', 'NCI CTCAE v4.0', 'National Cancer Institute Common Terminology Criteria for Adverse Events', 'version 4.0', 'NYHA', 'New York Heart Association', 'os', 'overall survival', 'P+H IV', 'Perjeta IV and Herceptin IV', 'pCR', 'pathologic complete response', 'Perjeta IV', 'Perjeta for IV administration', 'PFS', 'progression-free survival', 'PgR', 'progesterone receptor', 'PK', 'pharmacokinetic(s)', 'PPQ', 'Patient Preference Questionnaire', 'PRO', 'patient reported outcome', 'QoL', 'quality of life', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '27 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}